Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH

Abstract

The COVID-19 pandemic is an ongoing global healthcare crisis. Based on reports of atypically located thromboses following vaccination with the AstraZeneca COVID-19 vaccine, the Society of Thrombosis and Haemostasis Research (GTH) has issued guidance statements on the recognition, diagnosis, and treatment of this rare complication. It shares pathophysiological features with heparin-induced thrombocytopenia (HIT) and is referred to as vaccine-induced prothrombotic immune thrombocytopenia (VIPIT).

Zusammenfassung

Die COVID-19 Pandemie stellt eine andauernde globale Gesundheitskrise dar. Basierend auf den Berichten über atypisch lokalisierte Thrombosen nach Impfung mit dem AstraZeneca COVID-19 Vakzin hat die Gesellschaft für Thrombose- und Hämostaseforschung (GTH) Handlungsempfehlungen zur Erkennung, Diagnostik und Therapie dieser seltenen Komplikation formuliert. Ihre Pathophysiologie ähnelt derjenigen der Heparin-induzierten Thrombozytopenie (HIT) und wird als Vakzin-induzierte prothrombotische Immunthrombozytopenie (VIPIT) bezeichnet.

Keywords

platelet antigens - thrombosis - SARS-CoV-2 - vaccine

Schlüsselwörter

Thrombo-zytenantigene - Thrombose - SARS-CoV-2 - Vakzin

Publication History

Received: 29 March 2021

Accepted: 30 March 2021

Article published online:
01 April 2021

• References

• 1 Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 2020; 324 (08) 782-793
• 2 Langer F, Kluge S, Klamroth R, Oldenburg J. Coagulopathy in COVID-19 and its implication for safe and efficacious thromboprophylaxis. Hamostaseologie 2020; 40 (03) 264-269
• 3 Nopp S, Moik F, Jilma B, Pabinger I, Ay C. Risk of venous thromboembolism in patients with COVID-19: a systematic review and meta-analysis. Res Pract Thromb Haemost 2020; 4 (07) 1178-1191
• 4 Accessed March 31, 2021 at: https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots
• 5 Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle P, Eichinger S. A prothrombotic thrombocytopenic disorder resembling heparin-induced thrombocytopenia following coronavirus-19 vaccination. Preprint: https://www.researchsquare.com/article/rs-362354/v1 DOI: 10.21203/rs.3.rs-362354/v1
• 6 Mohanty E, Nazir S, Sheppard JI, Forman DA, Warkentin TE. High-dose intravenous immunoglobulin to treat spontaneous heparin-induced thrombocytopenia syndrome. J Thromb Haemost 2019; 17 (05) 841-844
• 7 Warkentin TE. High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review. Expert Rev Hematol 2019; 12 (08) 685-698
• 8 Haas S, Encke A, Kopp I. [German S3 practice guidelines on prevention of venous thromboembolism--new and established evidence]. Dtsch Med Wochenschr 2016; 141 (07) 453-456
• 9 Haas S, Encke A, Kopp I. German S3 guideline for the prevention of venous thromboembolism updated comment on Vasa Supplement 92. Vasa 2016; 45 (05) 347-348